Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• The TP53 gene is frequently mutated in human cancers.
• Accurate clinical evaluation of TP53 variants is essential for predicting treatment response and patient outcomes.
• Current understanding of TP53 architecture and variant impact is incomplete.

Purpose of the Study:

• To describe the complex architecture of the TP53 gene, including novel regulatory regions and their implications for tumor suppressor activity.
• To establish a standardized framework for the clinical evaluation of TP53 variants, enhancing diagnostic sensitivity and specificity.
• To provide a functional classification of TP53 variants based on a large dataset.

Main Methods:

• Identification of an intronic promoter and two novel exons in the TP53 gene.
• Analysis of TP53 transcripts and protein isoforms.
• Statistical analysis of over 45,000 variants from the UMD TP53 database.
• Application of Locus Reference Genomic (LRG) sequence and Human Genome Variation Society (HGVS) recommendations.

Main Results:

• Discovery of novel regions within TP53 that are targets for mutations, affecting tumor suppressive functions.
• Development of a comprehensive description framework for TP53 variants, enabling standardized data annotation and exchange.
• Statistical classification of the functional effects (pathogenicity) of over 45,000 TP53 variants.

Conclusions:

• The complex architecture of TP53 necessitates reassessment of variants in newly identified regions for refined prognostic value.
• A standardized approach using LRG and HGVS recommendations is crucial for accurate TP53 variant reporting and clinical utility.
• The provided variant classification aids in understanding TP53's role in various malignancies and guides therapeutic strategies.